11.78% -0.15

Biofrontera Inc (BFRI)

概要ニュース株価時系列 Financials ディスカッション予測株式分割

Relative Volume:

ネットキャッシュフロー:

Biofrontera Inc Stock (BFRI) Company Profile

Biofrontera Inc

Healthcare (1233)

781-245-1325

120 PRESIDENTIAL WAY,, WOBURN

BFRI's Discussions on Twitter

BFRI を他の銘柄と比較する

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
BFRI Biofrontera Inc	1.03	8.92M	34.07M	-20.13M	-24.90M	-12.92
ZTS Zoetis Inc	164.81	73.93B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.145	41.66B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	13.09	41.52B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	21.00	23.79B	16.77B	-959.00M	1.37B	-0.85
VTRS Viatris Inc	11.62	13.88B	15.05B	-883.30M	1.89B	-0.74

Biofrontera Inc (BFRI) 最新ニュース

Biofrontera Inc (BFRI) 財務データ

Biofrontera Inc (BFRI)

Biofrontera Inc Stock (BFRI) Company Profile

BFRI を他の銘柄と比較する

Biofrontera Inc (BFRI) 最新ニュース

Biofrontera says last patient completed one-year follow-up in Ameluz-PDT study - TipRanks

Biofrontera Inc. Announces Achievement of Key Milestone In - GlobeNewswire

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - Yahoo Finance

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - The Manila Times

Biofrontera Hits Major Milestone: 100th RhodoLED® XL Lamp Installed as PDT Treatment Demand Surges - StockTitan

Opendoor Technologies Inc (OPEN-Q) QuotePress Release - The Globe and Mail

Financial Contrast: Biofrontera (NASDAQ:BFRI) versus Amicus Therapeutics (NASDAQ:FOLD) - Defense World

Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga

Biofrontera Inc (BFRI:UR): Stock Price, Quote and News - BNN Bloomberg

Biofrontera to Present at Benchmark's Discovery Investor Conference in NYC - StockTitan

Biofrontera Inc. announced that it expects to receive $4.2 million in funding - Marketscreener.com

Biofrontera Closes a $4.2 Million Senior Secured Convertible Note - citybiz

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - GlobeNewswire

Biofrontera Secures $4.2M for Strategic Growth Initiatives - TipRanks

Biofrontera Secures $4.2M Financing Through Convertible Note Deal with Key Shareholders | BFRI Stock News - StockTitan

Biofrontera AG announced that it has received $4.2 million in funding - Marketscreener.com

Biofrontera Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Earnings call: Biofrontera reports modest revenue growth in Q3 2024 - Investing.com

Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Call Transcript - Insider Monkey

Biofrontera Inc. (BFRI) Quarterly 10-Q Report - Quartzy

ARMISTICE CAPITAL, LLC Acquires New Stake in Biofrontera Inc - GuruFocus.com

Biofrontera Inc. Reports Q3 2024 Earnings Growth - TipRanks

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - MSN

Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewswire

Biofrontera Reports Record Ameluz Volume, Phase 3 Study Shows 76% Clearance Rate | BFRI Stock News - StockTitan

Siga Technologies (SIGA) Sees Significant Stock Decline Amidst P - GuruFocus.com

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc. - GuruFocus.com

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance

Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia

Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance

Biofrontera Announces Promising Phase 3 Study Results - TipRanks

Biofrontera reports breakthrough in skin cancer treatment - Investing.com

Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewswire

Actinic Keratosis Treatment Market Expected to Reach Huge - openPR

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance

Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia

Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India

Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan

BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Mass. Biotech Receives FDA Approval - Streetwise Reports

Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa

Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India

What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News

Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks

Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks

FDA approves expanded use of Biofrontera's Ameluz for AK - Investing.com

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - The Manila Times

Biofrontera Inc (BFRI) 財務データ

収益

当期純利益

現金流量

EPS

BFRIに似た銘柄